From Name:
From Email:
To Name:
To Email:

Optional Message:


New approach may overcome breast cancer resistance to HER2-targeted therapies

from Oncology Nurse Advisor

Resistance to a combination of human epidermal growth factor receptor 2 (HER2)-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being developed. These preclinical results were presented at the American Association for Cancer Research 2014 Annual Meeting, in San Diego, California. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063